Mystic Pharmaceuticals Receives U.S. Patent For Needle-Free Vaccine and Drug Delivery Technology
4/22/2010 9:44:55 AM
AUSTIN, Texas--(BUSINESS WIRE)--Mystic Pharmaceuticals today announced it has been granted U.S. Patent 7,669,597, a key technology of its VRx2™ drug delivery platform. The VRx2™ Delivery Platform provides preservative free, precision dose delivery for ophthalmic and intranasal drugs and biologics. The issued patent covers Mystic’s proprietary unit dose blister technology for packaging of drugs or biologics that have been freeze dried to powder form to improve stability, reduce the need for cold chain management and enable auto-reconstitution to a liquid form at the time of administration.
comments powered by